Revvity, Inc. (NYSE:RVTY) Plans Quarterly Dividend of $0.07

Revvity, Inc. (NYSE:RVTY) declared a quarterly dividend on Thursday, April 25th, RTT News reports. Stockholders of record on Friday, July 19th will be given a dividend of 0.07 per share on Friday, August 9th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.28%.

Revvity has a payout ratio of 5.4% indicating that its dividend is sufficiently covered by earnings. Analysts expect Revvity to earn $5.20 per share next year, which means the company should continue to be able to cover its $0.28 annual dividend with an expected future payout ratio of 5.4%.

Revvity Trading Down 0.6 %

NYSE:RVTY opened at $101.51 on Friday. Revvity has a 12 month low of $79.50 and a 12 month high of $132.54. The firm has a market cap of $12.54 billion, a price-to-earnings ratio of 18.46, a P/E/G ratio of 2.66 and a beta of 1.09. The company has a quick ratio of 1.77, a current ratio of 2.07 and a debt-to-equity ratio of 0.40. The company’s 50 day moving average is $104.66 and its 200-day moving average is $101.46.

Revvity (NYSE:RVTY) last announced its earnings results on Thursday, February 1st. The company reported $1.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.15 by $0.10. Revvity had a net margin of 25.20% and a return on equity of 7.41%. The business had revenue of $695.90 million for the quarter. Equities analysts anticipate that Revvity will post 4.65 EPS for the current year.

Analyst Upgrades and Downgrades

RVTY has been the topic of a number of research reports. Evercore ISI raised shares of Revvity from an “in-line” rating to an “outperform” rating and boosted their target price for the stock from $88.00 to $125.00 in a research report on Thursday, January 4th. Barclays boosted their target price on shares of Revvity from $92.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Thursday, January 25th. Stifel Nicolaus boosted their target price on shares of Revvity from $95.00 to $110.00 and gave the stock a “hold” rating in a research report on Friday, February 2nd. KeyCorp lifted their price target on shares of Revvity from $110.00 to $126.00 and gave the stock an “overweight” rating in a research note on Friday, February 2nd. Finally, Raymond James lifted their price target on shares of Revvity from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Friday, February 2nd. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $118.91.

Insider Activity

In other news, insider Prahlad R. Singh sold 21,217 shares of the business’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $104.28, for a total value of $2,212,508.76. Following the sale, the insider now owns 92,801 shares in the company, valued at approximately $9,677,288.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.60% of the stock is owned by corporate insiders.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.